LU91017I2 - Cialis-tadalafil et les sels et solvates physiologiquement acceptables de celui-ci - Google Patents

Cialis-tadalafil et les sels et solvates physiologiquement acceptables de celui-ci

Info

Publication number
LU91017I2
LU91017I2 LU91017C LU91017C LU91017I2 LU 91017 I2 LU91017 I2 LU 91017I2 LU 91017 C LU91017 C LU 91017C LU 91017 C LU91017 C LU 91017C LU 91017 I2 LU91017 I2 LU 91017I2
Authority
LU
Luxembourg
Prior art keywords
3alkyl
alkyl
represents hydrogen
ring
solvates
Prior art date
Application number
LU91017C
Other languages
English (en)
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corp filed Critical Icos Corp
Publication of LU91017I2 publication Critical patent/LU91017I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU91017C 1994-01-21 2003-03-26 Cialis-tadalafil et les sels et solvates physiologiquement acceptables de celui-ci LU91017I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds
PCT/EP1995/000183 WO1995019978A1 (fr) 1994-01-21 1995-01-19 Derives tetracycliques, leurs procedes de preparation et leur utilisation

Publications (1)

Publication Number Publication Date
LU91017I2 true LU91017I2 (fr) 2003-05-26

Family

ID=10749089

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91017C LU91017I2 (fr) 1994-01-21 2003-03-26 Cialis-tadalafil et les sels et solvates physiologiquement acceptables de celui-ci

Country Status (49)

Country Link
US (5) US5859006A (fr)
EP (1) EP0740668B1 (fr)
JP (3) JP3808095B2 (fr)
KR (1) KR100357411B1 (fr)
CN (2) CN1045777C (fr)
AP (1) AP556A (fr)
AT (1) ATE169018T1 (fr)
AU (2) AU689205B2 (fr)
BG (1) BG62733B1 (fr)
BR (1) BR9506559C8 (fr)
CA (1) CA2181377C (fr)
CO (1) CO4340684A1 (fr)
CZ (1) CZ286566B6 (fr)
DE (2) DE69503753T2 (fr)
DK (1) DK0740668T3 (fr)
EE (1) EE03231B1 (fr)
EG (1) EG25852A (fr)
ES (1) ES2122543T3 (fr)
FI (1) FI113176B (fr)
GB (1) GB9401090D0 (fr)
HK (1) HK1013286A1 (fr)
HR (1) HRP950023B1 (fr)
HU (1) HU222494B1 (fr)
IL (1) IL112384A (fr)
IN (1) IN183942B (fr)
IS (1) IS1888B (fr)
LU (1) LU91017I2 (fr)
LV (1) LV11690B (fr)
MA (1) MA23433A1 (fr)
MX (1) MX9602904A (fr)
MY (1) MY114663A (fr)
NL (1) NL300124I2 (fr)
NO (2) NO306465B1 (fr)
NZ (1) NZ279199A (fr)
OA (1) OA10584A (fr)
PE (1) PE49495A1 (fr)
PL (1) PL179744B1 (fr)
RO (1) RO117794B1 (fr)
RU (1) RU2142463C1 (fr)
SA (1) SA95150475B1 (fr)
SG (1) SG49184A1 (fr)
SI (1) SI0740668T1 (fr)
SK (1) SK280879B6 (fr)
SV (1) SV1995000002A (fr)
TN (1) TNSN95004A1 (fr)
TW (1) TW378210B (fr)
UY (1) UY23893A1 (fr)
WO (1) WO1995019978A1 (fr)
ZA (1) ZA95424B (fr)

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6046216A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
IL126951A0 (en) * 1996-05-10 1999-09-22 Icos Corp Carboline derivatives
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
JP2002505676A (ja) * 1997-06-23 2002-02-19 クイーンズ ユニバーシティー アット キングストン 微量投与療法
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6211220B1 (en) 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
JP2002539247A (ja) 1999-03-24 2002-11-19 ハーバー ブランチ オーシャノグラフィック インスティテューション インク． マンズアミンの抗炎症作用の使用
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
NO20002097L (no) * 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
EP1200090B1 (fr) 1999-08-03 2013-09-11 ICOS Corporation Formulation pharmaceutique à base d'une béta-carboline et son utilisation pour traiter le dysfonctionnement sexuel
EA200200240A1 (ru) 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6562830B1 (en) 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
CA2411008C (fr) 2000-06-07 2006-04-11 Lilly Icos Llc Derives de 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4b]indole-1,4-dione
CA2412594C (fr) * 2000-06-23 2009-03-17 Lilly Icos Llc Derives de pyrazino[1',2':1,6]pyrido[3-4-5] indole
ATE333457T1 (de) * 2000-06-23 2006-08-15 Lilly Icos Llc Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ES2247138T3 (es) * 2000-06-26 2006-03-01 Lilly Icos Llc Derivados de pirazindiona condensados como inhibidores pde5.
CN1252055C (zh) * 2000-07-24 2006-04-19 拜尔农作物科学股份公司 联苯甲酰胺类化合物
CA2423357C (fr) * 2000-08-02 2008-05-27 Lilly Icos Llc Derives heterocycliques fusionnes utilises comme inhibiteurs de phosphodiesterase
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE297926T1 (de) * 2000-10-02 2005-07-15 Lilly Icos Llc Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
MXPA03002909A (es) 2000-10-02 2003-09-10 Lilly Icos Llc Compuestos quimicos.
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
EP1211313A3 (fr) * 2000-11-01 2003-04-23 Pfizer Limited Modulation de l'activité PDE11A activity
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
WO2002036593A1 (fr) * 2000-11-06 2002-05-10 Lilly Icos Llc Derives d'indole utilises comme inhibiteurs de pde5
WO2002088123A1 (fr) * 2001-04-25 2002-11-07 Lilly Icos Llc Composes chimiques
CA2445460A1 (fr) 2001-06-05 2002-12-12 Lilly Icos Llc Derives de carboline utilises comme inhibiteurs de pde-5
WO2002098877A1 (fr) * 2001-06-05 2002-12-12 Lilly Icos Llc Derives pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione
ES2286291T3 (es) * 2001-06-05 2007-12-01 Lilly Icos Llc Compustos tetraciclicos como inhibidores de pde5.
DE60213798T2 (de) 2001-06-21 2007-08-16 Lilly Icos Llc, Wilmington Carbolinderivate als pdev inhibitoren
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
JP2005509038A (ja) * 2001-11-09 2005-04-07 シェーリング　コーポレイション 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
ES2289159T3 (es) * 2001-11-14 2008-02-01 Ortho-Mcneil Pharmaceutical Corporation Derivados tetraciclicos sustituidos de pirroloquinolona utilizados como inhibidores de fosfodiesterasa.
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1506015A2 (fr) * 2002-05-23 2005-02-16 Pfizer Limited Combinaison pharmaceutique d'inhibiteurs pde5 et d'inhibiteurs de l'enzyme de conversion de l'angiotensine (ace)
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
BR0313070B1 (pt) * 2002-07-31 2014-09-09 Icos Corp Métodos para preparação de um diastereômero desejado de uma tetraidro-beta-carbolina e para preparação de um composto
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (fr) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
EA200501548A1 (ru) 2003-04-01 2006-02-24 Апплайд Резеч Системз Арс Холдинг Н.В. Ингибиторы фосфодиэстераз при бесплодии
EP1620437B1 (fr) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo 4,3-d]pyrimidines utiles pour le traitement de l'hypertension
EP1628682B1 (fr) * 2003-05-22 2013-09-25 Takeda GmbH Composition contenant un inhibiteur de pde4 et un inhibiteur de pde5 pour le traitement de copd
DK1644021T3 (da) * 2003-06-13 2012-10-29 Ironwood Pharmaceuticals Inc Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
EP1637521B1 (fr) 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Nouveau compose heterocyclique tricyclique
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
WO2005058280A2 (fr) * 2003-12-12 2005-06-30 Myogen, Inc. Preparations a base d'enoximone et leur utilisation pour traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
WO2005068464A2 (fr) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Procede de preparation de tadalafil et ses intermediaires
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20060025463A1 (en) * 2004-03-22 2006-02-02 Michael Bristow Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
US20060030611A1 (en) * 2004-03-22 2006-02-09 Myogen, Inc. Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseases
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
WO2005116030A1 (fr) * 2004-05-31 2005-12-08 Matrix Laboratories Ltd Procede d'elaboration de tadalafil
EP1776108A1 (fr) * 2004-06-23 2007-04-25 Myogen, Inc. Formulations d'enoximone et utilisation dans le traitement de maladies a mediation par pde-iii
CA2577442A1 (fr) 2004-08-17 2006-03-02 The Johns Hopkins University Compositions d'inhibiteur pde5 et methodes de traitement des troubles cardiaques
US8063214B2 (en) * 2004-10-28 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of tadalafil
EP1799216A2 (fr) * 2004-11-02 2007-06-27 Teva Pharmaceutical Industries Ltd Formes cristallines de tadalafil et leurs procedes de preparation
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP4997976B2 (ja) 2004-12-22 2012-08-15 小野薬品工業株式会社 三環式化合物およびその用途
MX2007010433A (es) * 2005-02-25 2007-10-11 Teva Pharma Tadafil que tiene un tamano de particula grande y un proceso para la preparacion del mismo.
MX2007009707A (es) * 2005-02-25 2007-09-12 Teva Pharma Proceso para sintetizar tadalafil.
WO2006091980A1 (fr) * 2005-02-25 2006-08-31 Teva Pharmaceutical Industries Ltd. Methode de purification de tadalafil
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
ES2278552T1 (es) * 2005-04-12 2007-08-16 Teva Pharmaceutical Industries Ltd Preparacion de intermediarios de tadalafil.
JP2008536888A (ja) 2005-04-19 2008-09-11 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺高血圧症の治療のためのロフルミラスト
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EA012577B1 (ru) 2005-05-12 2009-10-30 Пфайзер Инк. БЕЗВОДНЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[1-(2-ЭТОКСИЭТИЛ)-5-(N-ЭТИЛ-N-МЕТИЛАМИНО)-7-(4-МЕТИЛПИРИДИН-2-ИЛАМИНО)-1Н-ПИРАЗОЛО[4,3-d]ПИРИМИДИН-3-КАРБОНИЛ]МЕТАНСУЛЬФОНАМИДА
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
EP2324886A1 (fr) 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Nouveaux analogues deutériés de tadalafil
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
CA2620333A1 (fr) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenese par modulation du recepteur muscarinique
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
CA2622200A1 (fr) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
SI2450041T1 (sl) 2005-10-12 2019-02-28 Unimed Pharmaceuticals, Llc Izboljšan testosteronski gel za uporabo pri zdravljenju hipogonadizma
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
WO2007048803A1 (fr) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
WO2007100387A2 (fr) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Procédé de préparation de tadalafil
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007104035A1 (fr) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2004644A1 (fr) * 2006-03-24 2008-12-24 Glenmark Pharmaceuticals Limited Procede de preparation de tadalafil
WO2007124045A2 (fr) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Potentialisation d'activité de récepteur mc4
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenese par modulation de l'angiotensine
EP2026813A2 (fr) 2006-05-09 2009-02-25 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
RU2009103660A (ru) * 2006-07-07 2010-08-20 Тева Фармасьютикал Индастриес Лтд. (Il) Твердые фармацевтические композиции, включающие тадалафил и по меньшей мере один носитель
PT2046292E (pt) 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
WO2008019996A2 (fr) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations de flibansérine et leur procédé de fabrication
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
EP2068872A1 (fr) * 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
PT2101777E (pt) 2006-12-12 2015-09-18 Gilead Sciences Inc Composição para tratar uma hipertensão pulmonar
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
KR20150089085A (ko) 2007-02-12 2015-08-04 브릭스 파마슈티컬스 인코퍼레이티드 조루 및 발기부전을 동시에 치료하는 방법
JP5550101B2 (ja) 2007-02-12 2014-07-16 ヴィリックス ファーマシューティカルズ インコーポレイテッド トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法
WO2008103470A2 (fr) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Composés létaux dépendants du signal de ras oncogénique
EP1985310B1 (fr) * 2007-04-25 2013-03-20 Teva Pharmaceutical Industries Ltd. Formes de dosage solide
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
KR20100027170A (ko) 2007-06-29 2010-03-10 랜박시 래보러터리스 리미티드 테트라사이클릭 화합물의 중간체의 제조 방법
EP2033962A1 (fr) * 2007-08-22 2009-03-11 4Sc Ag Dérivés tétracycliques d'indolopyridines comme inhibiteurs de EG5
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2009091777A1 (fr) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Le nébivolol dans le traitement du dysfonctionnement sexuel
ITMI20080285A1 (it) * 2008-02-22 2009-08-23 Endura Spa Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
EP2107059A1 (fr) 2008-03-31 2009-10-07 LEK Pharmaceuticals D.D. Conversion de tryptophane en dérivés de ß-carboline
PL385356A1 (pl) 2008-06-03 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania tadalafilu
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2181997A1 (fr) 2008-10-30 2010-05-05 Chemo Ibérica, S.A. Procédé de préparation de tadalafil
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
EP2379076B1 (fr) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Inhibiteurs de la phosphodiestérase et utilisations de ces derniers
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP6074142B2 (ja) 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) * 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
EP2556820A4 (fr) 2010-04-05 2015-01-21 Sk Chemicals Co Ltd Composition contenant un inhibiteur de pde5 pour l'atténuation des rides de la peau
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
NZ707213A (en) 2010-10-15 2016-12-23 Gilead Sciences Inc Compositions and methods of treating pulmonary hypertension
EP2672959A1 (fr) 2011-02-10 2013-12-18 Synthon BV Composition de granulés comportant du tadalafil et un délitant
WO2012107549A1 (fr) 2011-02-10 2012-08-16 Interquim, S.A. PROCÉDÉ POUR L'OBTENTION DE COMPOSÉS ISSUS DE TÉTRAHYDRO-ß-CARBOLINE
WO2012107092A1 (fr) 2011-02-10 2012-08-16 Synthon Bv Composition pharmaceutique comportant du tadalafil et une cyclodextrine
WO2012107541A1 (fr) 2011-02-10 2012-08-16 Synthon Bv Composition pharmaceutique comprenant du tadalafil et une cyclodextrine
US20120123124A1 (en) * 2011-04-22 2012-05-17 Drug Process Licensing Associates, LLC Manufacturing process for Tadalafil from racemic or L-tryptophan
CN102180876B (zh) * 2011-05-28 2016-05-18 浙江华海药业股份有限公司 一种他达那非晶型i的制备方法
EP2535049A1 (fr) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil pour le traitement de la démence
CN102367253B (zh) * 2011-09-20 2016-04-06 浙江华海药业股份有限公司 一种制备他达拉非晶型a的方法
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013106547A1 (fr) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
WO2013109738A1 (fr) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
WO2013109227A1 (fr) 2012-01-18 2013-07-25 Mahmut Bilgic Compositions pharmaceutiques contenant du ceftibutène
WO2013109223A1 (fr) 2012-01-18 2013-07-25 Mahmut Bilgic Formulations de particules de tadalafil sous forme effervescente
WO2013109230A1 (fr) 2012-01-18 2013-07-25 Mahmut Bilgic Compositions pharmaceutiques contenant du tadalafil
CA2864322C (fr) 2012-02-28 2016-08-09 Seoul Pharma. Co., Ltd. Film a haute teneur et a dissolution rapide a gout amer masque comprenant du sildenafil comme principe actif
WO2014055801A1 (fr) 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
ES2903151T3 (es) 2012-12-04 2022-03-31 Aribio Inc Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
EP3470070B1 (fr) 2012-12-21 2021-04-28 Mayo Foundation for Medical Education and Research Procédés et matériaux pour le traitement de la sténose valvulaire aortique calcifiée
KR20150119871A (ko) 2013-02-21 2015-10-26 아드베리오 파마 게엠베하 메틸 ｛4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리디노-3-일]피리미디노-5-일｝메틸 카르바메이트의 형태
CN103232451A (zh) * 2013-05-14 2013-08-07 张家港威胜生物医药有限公司 一种他达那非的简易制备工艺
WO2015009930A2 (fr) 2013-07-17 2015-01-22 The Trustees Of Columbia University In The City Of New York Nouveaux inhibiteurs de la phosphodiestérase et utilisations de ceux-ci
EP3082428A4 (fr) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
WO2016001143A1 (fr) 2014-06-30 2016-01-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations de tadalafil à délitement buccal
EP2962684A1 (fr) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de tadalafil se désintégrant par voie orale
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
EA035390B1 (ru) 2014-07-23 2020-06-05 КРКА, д.д., НОВО МЕСТО Совместный осадок тадалафила с фармацевтически приемлемыми эксципиентами, содержащая его фармацевтическая композиция и способ их получения
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
AU2015399642B2 (en) * 2015-06-26 2020-04-09 Chongqing Dikang Erle Pharma Co. Ltd. Novel phosphodiesterase type-5 inhibitor and application thereof
CN105541840B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 关键中间体及其合成方法和在制备他达拉非方面的应用
CN105541835B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
BR112019012251A2 (pt) 2016-12-14 2019-11-05 Respira Therapeutics Inc métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
RU2692764C1 (ru) 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила
CN111995658B (zh) * 2019-05-27 2022-08-02 首都医科大学 Ldv修饰的五环哌嗪二酮及其制备和应用
BR112021024894A2 (pt) 2019-07-15 2022-01-25 Biolab Sanus Farmaceutica Ltda Estereoisômeros do composto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hidroxipropan-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a]pirazina-5,8-diona e seu uso como antitumoral e inibidor da enzima fosfodiesterase
CN110606847A (zh) * 2019-07-30 2019-12-24 中国医药集团总公司四川抗菌素工业研究所 一种他达拉非顺式中间体的制备方法及其应用
WO2021245192A1 (fr) 2020-06-04 2021-12-09 Topadur Pharma Ag Nouveaux activateurs de la guanylate cyclase soluble à double mode d'action et inhibiteurs de phosphodiestérase et leurs utilisations
WO2024173675A1 (fr) 2023-02-16 2024-08-22 University Of Rochester Amélioration de l'efflux glymphatique-lymphatique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
EP0357122A3 (fr) * 1988-08-29 1991-10-23 Duphar International Research B.V L'application des bêta-carbolines, benzofurane et benzothiophène analogues pour obtenir un médicament à activité cytostatique
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance

Also Published As

Publication number Publication date
SV1995000002A (es) 1995-10-04
US6025494A (en) 2000-02-15
JP2004217674A (ja) 2004-08-05
NO963015D0 (no) 1996-07-19
EP0740668A1 (fr) 1996-11-06
SI0740668T1 (en) 1999-02-28
JPH09508113A (ja) 1997-08-19
HK1013286A1 (en) 1999-08-20
NO2003002I2 (no) 2005-03-21
MX9602904A (es) 1997-12-31
NO306465B1 (no) 1999-11-08
CN1045777C (zh) 1999-10-20
NZ279199A (en) 1998-01-26
JP3808095B2 (ja) 2006-08-09
CA2181377A1 (fr) 1995-07-27
GB9401090D0 (en) 1994-03-16
OA10584A (en) 2002-08-26
PE49495A1 (es) 1996-01-10
BR9506559A (pt) 1997-10-28
LV11690B (en) 1997-06-20
CA2181377C (fr) 2002-05-28
US5859006A (en) 1999-01-12
AP9500712A0 (en) 1995-01-31
SG49184A1 (en) 1998-05-18
RO117794B1 (ro) 2002-07-30
NL300124I2 (nl) 2003-11-03
ZA95424B (en) 1995-09-27
UY23893A1 (es) 1995-07-11
AU707055B2 (en) 1999-07-01
HRP950023B1 (en) 2000-10-31
EG25852A (en) 2012-09-10
US6784179B2 (en) 2004-08-31
DK0740668T3 (da) 1999-05-03
SK280879B6 (sk) 2000-08-14
DE10399006I2 (de) 2004-05-06
KR100357411B1 (ko) 2003-02-05
AU689205B2 (en) 1998-03-26
CN1224720A (zh) 1999-08-04
IL112384A0 (en) 1995-03-30
JP2009102386A (ja) 2009-05-14
FI113176B (fi) 2004-03-15
CN1070492C (zh) 2001-09-05
RU2142463C1 (ru) 1999-12-10
HU222494B1 (hu) 2003-07-28
PL315559A1 (en) 1996-11-12
AU1574895A (en) 1995-08-08
IS4252A (is) 1995-07-22
EE03231B1 (et) 1999-10-15
CO4340684A1 (es) 1996-07-30
CZ286566B6 (cs) 2000-05-17
AU7391298A (en) 1998-08-20
ES2122543T3 (es) 1998-12-16
WO1995019978A1 (fr) 1995-07-27
CZ211696A3 (en) 1997-06-11
NO2003002I1 (no) 2003-01-22
EP0740668B1 (fr) 1998-07-29
TNSN95004A1 (fr) 1996-02-06
IL112384A (en) 1998-08-16
DE10399006I1 (de) 2003-07-31
FI962927A (fi) 1996-07-19
NL300124I1 (nl) 2003-07-01
LV11690A (lv) 1997-02-20
AP556A (en) 1996-11-07
DE69503753D1 (de) 1998-09-03
MY114663A (en) 2002-12-31
FI962927A0 (fi) 1996-07-19
BG62733B1 (bg) 2000-06-30
IS1888B (is) 2003-09-01
SK94096A3 (en) 1997-04-09
US6127542A (en) 2000-10-03
HU9601982D0 (en) 1996-09-30
US6369059B1 (en) 2002-04-09
SA95150475B1 (ar) 2005-07-31
TW378210B (en) 2000-01-01
IN183942B (fr) 2000-05-20
PL179744B1 (pl) 2000-10-31
US20020119976A1 (en) 2002-08-29
BG100727A (bg) 1997-02-28
HRP950023A2 (en) 1998-04-30
CN1143963A (zh) 1997-02-26
ATE169018T1 (de) 1998-08-15
NO963015L (no) 1996-09-09
HUT74943A (en) 1997-03-28
MA23433A1 (fr) 1995-10-01
BR9506559C8 (pt) 2020-07-07
JP4347125B2 (ja) 2009-10-21
DE69503753T2 (de) 1999-01-21

Similar Documents

Publication Publication Date Title
LU91017I2 (fr) Cialis-tadalafil et les sels et solvates physiologiquement acceptables de celui-ci
CA2340636A1 (fr) Combinaisons d'inhibiteurs de phosphodiesterase tetracyclique cyclique specifique de gmp avec d'autres agents therapeutiques
EA199800907A1 (ru) Производные карболина
MX9800415A (es) Compuestos quimicos.
ATE368665T1 (de) Oxindolylchinazolinderivate als angiogenesehemmer
ES2051772T3 (es) 2-sustituido-e-fusionado-(1,2,4)-triazol(1,5-c)pirimidinas, composiciones farmaceuticas y sus usos.
CA2445625A1 (fr) Derives de pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione
FI921308A0 (fi) Foerfarande foer framstaellning av derivat av substituerad imidazol-2-on.
DK0888356T3 (da) Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere
SE9701396D0 (sv) Compounds
ATE500241T1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
MD980248A (ro) Derivaţi ai carbolinei